Clinical trial · Observational
Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer
NCT01671891CI-TRIAL-00007887unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Rectal cancer is one of the most common malignant tumors in the world. However, there's also no reliable and sensitive method to monitor diseases and evaluate therapy responses till now. Circulating tumor cells, which could reflect tumor's status correctly and reliably, may be a promising method in this field. This study is to investigate the role of circulating tumor cells in evaluating and predicting the responses of chemoradiotherapy in rectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw) | Drug | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- rectal cancer with stage II-IV
- description
- rectal cancer with stage II-IV intervention: pelvic radiotherapy (45-55Gy) concurrent chemotherapy using capecitabine and oxaliplatin
- interventionNames
- Radiation: radiation therapy
- Drug: capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)
Primary outcomes (1)
- measure
- circulating tumor cells level changes after radiotherapy
- timeFrame
- 3 years
Secondary outcomes (5)
- measure
- overall survival
- timeFrame
- 3 years
- measure
- disease-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically verified rectal carcinoma * Locally advanced tumor (cT3-4 and/or N+ by transrectal ultrasound and/or pelvic magnetic resonance imaging) * the distance from anal verge \<= 12cm * with or without metastasis * Age 18-75 years old * ECOG PS 0-2 * No previous chemotherapy or radiotherapy for rectal carcinoma * Written informed consent Exclusion Criteria: * no histologically verified rectal carcinoma * rectal cancer with stage I * distance from verge \>12cm * age \<=18 or \>=75 years old * performed previously chemotherapy or radiotherapy * infection diseases within three months * serious other diseases * no written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.